Alnylam Pharmaceuticals faces significant market pressures as shares continue to decline amidst ongoing scrutiny.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) is experiencing a notable downturn, with its stock price dropping 1.99% to close at CA$228.04. This decline follows a series of concerning developments that have raised questions about the company's future prospects.
Investor takeaway: Investors are increasingly wary of Alnylam's valuation and the implications of ongoing legal scrutiny, leading to a reevaluation of the stock's attractiveness.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$31.13B
P/E
39.2x
52W high
$495.55
52W low
$197.81
1W change
+5.90%
Beta
0.27
Analyst Price Targets
Based on 29 analysts covering ALNY · as of Oct 12, 2026
Wall Street analysts forecast ALNY stock price to rise 59.3% over the next 12 months.
Consensus
Buy4.31 / 5.00
Avg. Target
C$370.55
+59.3% Upside
Previously C$371.12 on Oct 5, 2026
Current Price
C$232.68
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
47.1%
Annualized
90-Day Vol
71.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$194.63
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$219.23 | C$186.37 – C$257.89 |
| 60 trading days | C$206.57 | C$164.18 – C$259.89 |
| 90 trading days | C$194.63 | C$146.91 – C$257.85 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
43.5% Year-to-Date Decline
Alnylam's shares have plummeted 43.5% year-to-date, reflecting investor concerns about the company's financial health and market position.
Bull case
Alnylam has a strong pipeline of RNAi therapies that could offer significant growth opportunities if clinical trials succeed and regulatory approvals are secured.
Bear case
The company is navigating a tough environment with legal investigations and disappointing sales expectations, which may hinder its ability to deliver on future earnings.
Market Reaction to Legal Scrutiny
Advertisement
Alnylam's stock price has been under pressure due to ongoing legal scrutiny related to its TTR franchise. Investors are worried that the company's valuation may not accurately reflect its earning potential, especially with reduced sales expectations. This uncertainty has led to a significant reevaluation of the stock, contributing to today's decline.
Valuation Concerns Amidst Declining Estimates
The company's P/E ratio of 39.24 suggests that investors are still paying a premium for Alnylam shares, despite a 43.5% drop in stock value this year. Recent earnings estimates have also been revised downward, further complicating the investment landscape for Alnylam as analysts weigh the risks associated with its current valuation.
Future Outlook Remains Clouded
With Alnylam's shares continuing to falter, the outlook for the company remains uncertain. The combination of legal challenges and disappointing sales forecasts raises questions about its ability to recover. Investors will need to closely monitor upcoming developments and clinical trial results to gauge the stock's future trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
